title: Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.
abstract: Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation therapies, and at the clinical level it is consistent with the development of rapidly progressive visceral disease, often in the absence of elevated serum prostate-specific antigen level. Until present, platinum-based chemotherapy has been the only treatment modality, able to produce a fair amount of responses but of short duration. Recently, several efforts for molecular characterization of this lethal phenotype have resulted in identification of novel signaling factors involved in microenvironment interactions, mitosis, and neural reprograming as potential therapeutic targets. Ongoing clinical testing of specific inhibitors of these targets, for example, Aurora kinase A inhibitors, in carefully selected patients and exploitation of expression changes of the target before and after manipulation is anticipated to increase the existing data and facilitate therapeutic decision making at this late stage of the disease when hormonal manipulations, even with the newest androgen-directed therapies are no longer feasible.
authors.affiliation: Department of Internal Medicine, Lutheran Medical Center , Brooklyn, NY , USA.
authors.forename: Panagiotis J
authors.initials: PJ
authors.lastname: Vlachostergios
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly , Larissa , Greece.
authors.forename: Christos N
authors.initials: CN
authors.lastname: Papandreou
keywords: androgen-independent; castration-resistant; neuroendocrine prostate cancer; small cell prostate carcinoma; targeted therapy